Physician profile
Kenneth D Moore
NPI 1184646473
$341,501.12
in general payments reported to CMS, 2019-2025
15 companies · $9,823 in 2025
The $9,823 reported for 2025 was more than what 87% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $131K · 2020: $79K · 2021: $36K · 2022: $57K · 2023: $13K · 2024: $16K · 2025: $9,823.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $38K · Food and Beverage: $951.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $38,000.00 |
| Food and Beverage | $950.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $340,525.20 | 2019-2025 | Mako |
| Innovation Technologies INC | $168.43 | 2022 | |
| Osteoremedies, LLC | $166.12 | 2025 | Blastx, Xperience |
| Orthalign INC | $147.32 | 2025 | Orthalign Plus |
| Sanara Medtech INC. | $146.16 | 2024 | Celleraterx |
| Biocomposites INC | $121.33 | 2023 | Stimulan |
| Illuminoss Medical, INC. | $64.12 | 2024 | |
| Convatec INC. | $26.26 | 2024 | |
| Conmed Corporation | $22.75 | 2025 | System 2450, Visiclear |
| Molnlycke Health Care US, LLC | $22.70 | 2025 | Mepilex Border Post-Op Ag |
| Vertex Pharmaceuticals Incorporated | $19.71 | 2025 | |
| Abbvie INC. | $19.61 | 2021 | |
| Becton, Dickinson and Company | $19.59 | 2025 | Arista |
| Amgen INC. | $16.20 | 2019 | |
| Smith+Nephew, INC. | $15.62 | 2025 | Renasys Go V2 Home |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.